ACE2 News and Research

RSS

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

In a new study, researchers examined the effect of electrostatic changes on the ability of the SARS-CoV-2 Omicron variant to escape immunity.

16 Feb 2022

Omicron RBD-ACE2 binding found to be stronger than wild type SARS-CoV-2 strain

Researchers recently investigated the effect of SARS-CoV-2 Omicron variant mutations on the binding of the receptor-binding domain and angiotensin-converting enzyme-2 to study the overall binding profile of the RBD-ACE2 system.

16 Feb 2022

Research suggests SARS-CoV-2 viral accessory proteins may play significant role in viral evolution

Researchers investigate SARS-CoV-2 mutations present across the whole genome of different SARS-CoV-2 variants.

15 Feb 2022

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Researchers study antibodies against various SARS-CoV-2 epitopes that may be responsible for neutralizing activities in recovered COVID-19 patients.

15 Feb 2022

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Investigators studying lung cells have discovered that the normal repair process that occurs after lung disease or injury appears to be incomplete but still ongoing in patients who died of COVID-19 and non-COVID acute respiratory distress syndrome (ARDS).

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Researchers suggest that extracellular vimentin may act as a coreceptor to allow for SARS-CoV-2 entry into cells.

14 Feb 2022

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

In a new study, researchers demonstrated the variations in the neutralizing antibody responses induced by SARS-CoV-2 vaccines in humans, non-human primates, and mice against the SARS-CoV-2 variants of concern.

14 Feb 2022

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

In a recent study published in Science Translational Medicine, researchers characterized a human antibody targeting betacoronaviruses (β-CoVs).

14 Feb 2022

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

A new study was based on the hypothesis that competitively inhibiting cellular furin and selectively targeting SARS-CoV-2 in the infected viral-producing cells is critical for therapeutic specificity.

14 Feb 2022

Researchers identify autoantibody targets in COVID-19 patients

In a new study, researchers have been investigating auto-immune responses to natural human antigens in COVID-19 patients.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

Testes found to be a viral reservoir for SARS-CoV-2 replication

In a recent study posted to the medRxiv* pre-print server, researchers used a suite of methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the testis of patients who died from coronavirus disease 2019 (COVID-19) to gain insights into SARS-CoV-2 tropism inside testis and its impact on male fertility.

13 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

A new study provided the structural basis for a robust interaction between the receptor-binding domain of the SARS-CoV-2 Omicron spike protein and mouse ACE2.

13 Feb 2022

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

In a new study, a team of researchers described the efficacy of ABP-310, a neutralizing antibody, against SARS-CoV-2 variants, including Omicron.

10 Feb 2022

The effect of Omicron mutations at the fundamental atomic scale level

The present study provided interesting insights into the interactions of AAs at the interface between SARS-CoV-2 spike and human ACE2 receptors.

10 Feb 2022

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

The recent success of Paxlovid has encouraged researchers to develop new anti-covid drugs. With this in mind, scientists from the University of Pennsylvania have been investigating a new synergistic treatment. Their research is released early as an unedited version of the manuscript to be published in the journal Nature.

9 Feb 2022

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

A new study compares antibody levels in newborns born from mothers vaccinated against COVID-19 and to maternal infection with SARS-CoV-2.

9 Feb 2022

How SARS-CoV-2 infection progresses throughout the respiratory system

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

9 Feb 2022

ACE2 News and Research

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

Omicron RBD-ACE2 binding found to be stronger than wild type SARS-CoV-2 strain

Research suggests SARS-CoV-2 viral accessory proteins may play significant role in viral evolution

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

Researchers identify autoantibody targets in COVID-19 patients

Nitazoxanide shows promise for COVID-19 treatment in animal model

Testes found to be a viral reservoir for SARS-CoV-2 replication

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

The effect of Omicron mutations at the fundamental atomic scale level

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

How SARS-CoV-2 infection progresses throughout the respiratory system

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News